Same-Day BLA Filings Show Pfizer Has Gained Ground On Novartis In Meningitis B
This article was originally published in The Pink Sheet Daily
Both companies have “breakthrough” therapy designations from FDA and both announced BLA filings on June 17, but Pfizer’s earlier completion of the rolling submission could give it an edge in the race to launch a meningitis B vaccine in the U.S.
You may also be interested in...
The first-mover advantage for Trumenba remains unclear as CDC’s Advisory Committee on Immunization Practices holds crucial sway on vaccine use and commercial success; ACIP will vote on use of meningitis B vaccines in high-risk groups and during outbreaks in February 2015, but more widespread use recommendations may not be issued until late next year.
FDA’s biologics center grants accelerated approval to the first U.S. vaccine targeting serogroup B meningococcal disease after a 4.5-month review; the vaccine is expected to come up for discussion, but not a vote, at CDC’s Advisory Committee on Immunization Practices meeting Oct. 30.
A new method of making vaccines, called bio-conjugation, may be more efficient and cost effective than chemical conjugation methods used by Pfizer for Prevnar and other vaccine makers, and it may address new pathogens too.